ACS chemical neuroscience molecule spotlight on dimebon

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations


Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

Original languageEnglish (US)
Pages (from-to)587-588
Number of pages2
JournalACS Chemical Neuroscience
Issue number9
StatePublished - Sep 15 2010
Externally publishedYes


  • AD
  • Alzheimer's Disease
  • Dimebon
  • Neurodegeneration
  • clinical trials

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on dimebon'. Together they form a unique fingerprint.

Cite this